Selpercatinib Receives Regular Approval for Non–Small Cell Lung Cancer

Selpercatinib was granted regular approval from the US FDA to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. A companion diagnostic test also was approved. Marketed as R...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	JAMA : the journal of the American Medical Association 2022-11, Vol.328 (17), p.1679-1679
1. Verfasser:	Larkin, Howard D
Format:	Artikel
Sprache:	eng
Schlagworte:	Gene fusion Lung cancer Metastases Non-small cell lung carcinoma Ret protein Small cell lung carcinoma Subgroups Thyroid Transfection
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!